WALL STREET JOURNAL COVERS EXSIGHT
WALL STREET JOURNAL COVERS NEW CROP OF VENTURE FIRMS INCLUDING EXSIGHT
RE-VANA THERAPEUTICS DELIVERS $3.2 MILLION
RE-VANA THERAPEUTICS DELIVERS $3.2 MILLION OVERSUBSCRIBED ROUND
EXSIGHT ANNOUNCES DTX INVESTMENT
EXSIGHT ANNOUNCES DTX INVESTMENT TO ENABLE DELIVERY OF RNA THERAPEUTICS
ELECTRIFYING VISION: ANNOUNCING OUR INVESTMENT IN 2C TECH
ELECTRIFYING VISION: ANNOUNCING OUR INVESTMENT IN 2C TECH
INTRODUCING THE EXSIGHT VENTURES SYNDICATE ON ANGELLIST
INTRODUCING THE EXSIGHT VENTURES SYNDICATE ON ANGELLIST
HIS KIND OF TOWN: FIRAS HOSTS OIS TV AT OIS@ASRS IN CHICAGO
HIS KIND OF TOWN: FIRAS HOSTS OIS TV AT OIS@ASRS IN CHICAGO
TREFOIL MOVES CLOSER TO A CLINICAL TRIAL
TREFOIL MOVES CLOSER TO A CLINICAL TRIAL: ANNOUNCING OUR FOLLOW ON INVESTMENT
QURA'S PROMISE: ENABLE SMARTER TREATMENT
QURA'S PROMISE: ENABLE SMARTER TREATMENT DECISIONS BASED ON BETTER INFORMATION
ONL THERAPEUTICS IS PIONEERING AN ENTIRELY NEW APPROACH TO PRESERVING SIGHT AND HALTING VISION LOSS
ONL THERAPEUTICS IS PIONEERING AN ENTIRELY NEW APPROACH TO PRESERVING SIGHT AND HALTING VISION LOSS
EXSIGHT PARTNER ALAN SPIRO JOINS INNOVATIVE ODYLIA THERAPEUTICS
EXSIGHT PARTNER ALAN SPIRO JOINS INNOVATIVE ODYLIA THERAPEUTICS
LENSGEN HITTING MILESTONES AND BROADENING PATENT PROTECTION
LENSGEN HITTING MILESTONES AND BROADENING PATENT PROTECTION
DR. RAHHAL CO-AUTHORS BREAKTHROUGH STEM CELL TRANSPLANT TRIAL TARGETING VISION LOSS
DR. RAHHAL CO-AUTHORS BREAKTHROUGH STEM CELL TRANSPLANT TRIAL TARGETING VISION LOSS